China NT Pharma Group Co (HKSE:01011) Total Liabilities : HK$737.63 Mil (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co Total Liabilities?

China NT Pharma Group Co's Total Liabilities for the quarter that ended in Jun. 2024 was HK$737.63 Mil.

China NT Pharma Group Co's quarterly Total Liabilities declined from Jun. 2023 (HK$1,425.51 Mil) to Dec. 2023 (HK$731.40 Mil) but then increased from Dec. 2023 (HK$731.40 Mil) to Jun. 2024 (HK$737.63 Mil).

China NT Pharma Group Co's annual Total Liabilities declined from Dec. 2021 (HK$1,428.63 Mil) to Dec. 2022 (HK$1,392.96 Mil) and declined from Dec. 2022 (HK$1,392.96 Mil) to Dec. 2023 (HK$731.40 Mil).

China NT Pharma Group Co Total Liabilities Historical Data

The historical data trend for China NT Pharma Group Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co Total Liabilities Chart

China NT Pharma Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,887.62

1,508.64

1,428.63

1,392.96

731.40

China NT Pharma Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial															1,402.87	1,392.96	1,425.51	731.40	737.63

China NT Pharma Group Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

China NT Pharma Group Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	727.458	+	(3.938	+	-1.1990408665952E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	731.40

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	359.987	-	-371.409
	=	731.40

China NT Pharma Group Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	733.788	+	(3.837	+	-1.1102230246252E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	737.63

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	364.694	-	-372.931
	=	737.63

China NT Pharma Group Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

China NT Pharma Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG

Website

http://www.ntpharma.com

China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.

Executives

Ieong Chong Mang
Golden Base Investment Limited
Shum Ning
Chin Yu
Ng Tit
Wang Minzhi	2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines